Jessica Karins

Falls Church

FDA Reporter at Inside Health Policy

FDA reporter at @InHealthPolicy. Send tips to [email protected]

Articles

HHS Moving Away From mRNA Vaccines, May Shift HPAI Response

1 week ago | insidehealthpolicy.com | Jessica Karins

HHS cancelled a contract with Moderna for the development and potential purchase of an mRNA vaccine targeting possible pandemic influenzas, creating uncertainty for a vaccine candidate that could provide protection against the currently circulating highly pathogenic avian influenza (HPAI).
American Lung Association: HHS Cuts Will Harm Anti-Smoking Efforts

1 week ago | insidehealthpolicy.com | Jessica Karins

The American Lung Association is raising alarms about the cumulative impact of funding cuts for tobacco programs across HHS and the elimination of the Centers for Disease Control and Prevention (CDC) Office on Smoking and Health, saying the federal cuts are harming states’ ability to maintain their own programs.
HHS, CMS Pressure Providers To Drop Gender-Affirming Care For Children

1 week ago | insidehealthpolicy.com | Jessica Karins

CMS is pressing hospitals that provide gender-affirming care to patients under age 19 to answer several questions on the treatments and their policies within the next 30 days, hinting that it could take enforcement action against hospitals that have policies the Trump administration objects to, while HHS also pressures providers and state medical boards to stop providing the treatments.
Judge Orders Admin To Restore Articles Mentioning Transgender Health

1 week ago | insidehealthpolicy.com | Jessica Karins

A federal judge in Massachusetts has blocked the Trump administration from removing medical articles from an HHS database because they include mentions of transgender people, calling it an unconstitutional violation of prohibitions on viewpoint discrimination.
OSTP Head: ‘Gold Standard’ Science Emphasizes Reproducibility, Rejects DEI

1 week ago | insidehealthpolicy.com | Jessica Karins

President Donald Trump’s top science advisor is seeking to define the administration’s focus on “gold standard” science as an approach that prioritizes reproducibility and allows for scientific dissent while rejecting diversity, equity and inclusion (DEI) as the president’s latest executive order on the topic is drawing backlash from many scientists who say the administration is aiming to tighten political control over science at HHS and other agencies.
Stakeholders Warn Private Sector Can’t Make Up For NIH Cuts

1 week ago | insidehealthpolicy.com | Maaisha Osman |Jessica Karins

The National Institutes of Health's suspension of dozens of university research grants risk stalling innovation that private companies can’t replicate, industry leaders warn, as early-career NIH scientists recently protested Director Jay Bhattacharya’s town hall over what the scientists describe as an inability to conduct research under the second Trump administration.
Alzheimer’s Advocates Wary Of RFK Jr.’s Rhetoric On Amyloid Drugs

1 week ago | insidehealthpolicy.com | Jessica Karins |Gabrielle Wanneh

HHS Secretary Robert F. Kennedy Jr.’s comments about fraudulent research in treating Alzheimer’s and alleged corruption at the National Institutes of Health (NIH) are raising the specter among advocates that there will be new restrictions on the controversial class of drugs that combat amyloid beta plague in the brain.
CDC Updates COVID Shot Recommendation Without Consulting ACIP

1 week ago | insidehealthpolicy.com | Jessica Karins

The Centers for Disease Control and Prevention (CDC) is no longer recommending pregnant women and children get COVID-19 vaccine booster shots, HHS Secretary Robert F. Kennedy Jr. announced Tuesday (May 27).
Trump Mandates New Federal Science Policy Embracing ‘Alternative’ Views, Hits Biden-Era COVID, DEI Policies

2 weeks ago | insidehealthpolicy.com | Jessica Karins

President Donald Trump signed an executive order Friday (May 23) that he says will restore “gold standard science,” directing the White House Office of Science and Technology Policy (OSTP) to lay out new scientific guidelines for the federal government and telling HHS and other agencies to rescind any scientific integrity policies issued since the prior Trump administration.
Makary Endorses COVID Cover-Up Theory, Other Safety Data Coming

2 weeks ago | insidehealthpolicy.com | Jessica Karins

As health stakeholders push back against FDA’s move to limit the authorization of COVID-19 booster shots, and its move to require more randomized clinical trials for vaccines, top FDA officials are endorsing the idea that a deliberate government cover-up concealed safety information about COVID vaccines and hinting information about injuries caused by other vaccines might be revealed in the near future.